Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.81 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 3/20 | 0.59 |
| ▸ | PDE2A | O00408 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14115735 | 0.89 | NR3C1 (0.63) | NR3C1PDE4BPGRPDE5APDE2A | |
| SCHEMBL4346039 | 0.87 | NR3C1 (0.84) | NR3C1PDE4BPGRPDE5A | |
| SCHEMBL4338651 | 0.86 | NR3C1 (0.82) | NR3C1PDE4BPGRPDE5A | |
| SCHEMBL3283022 | 0.84 | NR3C1 (0.77) | NR3C1PDE4BPGRPDE5A | |
| SCHEMBL4810313 | 0.83 | NR3C1 (0.56) | NR3C1PDE4BPGRPDE5APDE2A | |
| SCHEMBL9835355 | 0.82 | PDE4B (0.55) | NR3C1PDE4BPGRPDE5A | |
| SCHEMBL4337611 | 0.81 | PDE4B (0.69) | NR3C1PDE4BPDE5A | |
| SCHEMBL4475060 | 0.81 | PDE4B (0.68) | NR3C1PDE4BPDE5A | |
| SCHEMBL4337128 | 0.81 | PDE4B (0.68) | NR3C1PDE4BPDE5A | |
| SCHEMBL4334228 | 0.80 | PDE5A (0.53) | NR3C1PDE4BPDE5APDE2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539753-B1 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| EP-1539753-B1 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
| EP-1539753-A2 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | PDE4B, PDE3B, PDE4A | NR3C1 964/4885PDE4B 1/4885PGR 2685/4885 |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | NR3C1 16/4885PDE4B 4/4885PGR 566/4885 |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | NR3C1 16/4885PDE4B 4/4885PGR 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.